IGHE and allergic asthma: In the UK, the NICE has approved the use of omalizumab in children aged 6 years and over with confirmed severe, persistent, IgE mediated allergic asthma, who require frequent treatment with oral corticosteroids (defined as four or more courses in the previous year) despite optimized therapy.